Evidence map›Paper›PMID 29508078›Full record

ArticlePharmaceutical research2018

Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells.

Mitchell P McInerney, Irene Volitakis, Ashley I Bush, William A Banks, Jennifer L Short, Joseph A Nicolazzo

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Clioquinol: To harm or heal.Pharmacology & therapeutics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mitchell P McInerneyDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences,, Monash University,, 381 Royal Parade, Parkville, VIC,, 3052, Australia.
Irene VolitakisThe Florey Institute of Neuroscience and Mental Health,, Parkville, VIC, Australia.
Ashley I BushThe Florey Institute of Neuroscience and Mental Health,, Parkville, VIC, Australia.
William A BanksDivision of Gerontology and Geriatric Medicine, Department of Medicine,, University of Washington School of Medicine, Seattle, Washington,, USA.
Jennifer L ShortDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University,, Parkville, VIC,, Australia.
Joseph A NicolazzoDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences,, Monash University,, 381 Royal Parade, Parkville, VIC,, 3052, Australia. joseph.nicolazzo@monash.edu.
Monash University · AUFlorey Institute of Neuroscience and Mental Health · AUUniversity of Washington · US

Funding

Bethlehem Griffiths Research Foundation BGRF1402National Health and Medical Research Council APP1048855The Mason Foundation CT20820
6 · The paper itself

Abstract

purposeBiometals such as zinc and copper have been shown to affect tight junction expression and subsequently blood-brain barrier (BBB) integrity. Whether these biometals also influence the expression and function of BBB transporters such as P-glycoprotein (P-gp) however is currently unknown.

methodsUsing the immortalised human cerebral microvascular endothelial (hCMEC/D3) cell line, an in-cell western assay (alongside western blotting) assessed relative P-gp expression after treatment with the metal ionophore clioquinol and biometals zinc and copper. The fluorescent P-gp substrate rhodamine-123 was employed to observe functional modulation, and inductively coupled plasma mass spectrometry (ICP-MS) provided information on biometal trafficking.

resultsA 24-h treatment with clioquinol, zinc and copper (0.5, 0.5 and 0.1 μM) induced a significant upregulation of P-gp (1.7-fold) assessed by in-cell western and this was confirmed with western blotting (1.8-fold increase). This same treatment resulted in a 23% decrease in rhodamine-123 accumulation over a 1 h incubation. ICP-MS demonstrated that while t8his combination treatment had no effect on intracellular zinc concentrations, the treatment significantly enhanced bioavailable copper (4.6-fold).

conclusionsEnhanced delivery of copper to human brain microvascular endothelial cells is associated with enhanced expression and function of the important efflux pump P-gp, which may provide therapeutic opportunities for P-gp modulation.

Indexed as

ATP Binding Cassette Transporter, Subfamily BBlood-Brain BarrierCell LineClioquinolEndothelial CellsEndothelium, VascularHumansIonophoresMicrovesselsTrace ElementsABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BClioquinolIonophoresTrace Elementsblood-brain barrierclioquinolionophoreP-glycoproteintransporter

Identifiers

PMID29508078
OpenAlexW2793506913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.